Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.85)
# 3,038
Out of 4,732 analysts
16
Total ratings
35.71%
Success rate
5.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $2.22 | +350.45% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $6 | $0.62 | +867.74% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $17.40 | +244.83% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $4.02 | +148.76% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $2.00 | +600.00% | 1 | Feb 21, 2023 | |
| TNXP Tonix Pharmaceuticals Holding | Initiates: Outperform | $3,840 | $0.24 | +1,630,473.25% | 1 | Apr 18, 2022 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $0.59 | +1,261.93% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $1.17 | +10,156.41% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $10.30 | - | 1 | Oct 5, 2020 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $12 | $9.21 | +30.29% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16,500 | $0.10 | +16,192,245.44% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.05 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.26 | +106.61% | 2 | Mar 8, 2018 |
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $2.22
Upside: +350.45%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $6
Current: $0.62
Upside: +867.74%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $17.40
Upside: +244.83%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $4.02
Upside: +148.76%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $2.00
Upside: +600.00%
Tonix Pharmaceuticals Holding
Apr 18, 2022
Initiates: Outperform
Price Target: $3,840
Current: $0.24
Upside: +1,630,473.25%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $0.59
Upside: +1,261.93%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $1.17
Upside: +10,156.41%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.30
Upside: -
Anavex Life Sciences
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $9.21
Upside: +30.29%
Aug 24, 2020
Initiates: Buy
Price Target: $16,500
Current: $0.10
Upside: +16,192,245.44%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $14.05
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $7.26
Upside: +106.61%